Sign in

Private company

Meridian Bioscience

Meridian Bioscience is an American medical equipment company based in Cincinnati, incorporated in Ohio.1

Last updated Oct 21, 2026.

Overview

1977Founded1
  • Industrymedical equipment1
  • HeadquartersCincinnati1
  • Listed onNasdaq (VIVO)1
  • Legal formCorporation (For-Profit)3
  • LEI549300ELSRZEFFFRX1953
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O CORPORATION SERVICE COMPANY, 43221 Columbus, United States3
  • Registered withCorporation Database (Ohio Secretary of State), 4833763

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

56.6%Gross margin4
16.3%Operating margin4
12.7%Net margin4
4.8%Revenue growth, 20224
11.5%Return on equity4
0.07×Debt to equity4
$73.7MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue43¢$144.7M
  • Research and development7¢$24.3M
  • Other costs33¢$108.5M
  • Interest0¢$1.2M
  • Income tax4¢$11.9M
  • Profit13¢$42.5M

Out of $333.0M in revenue.4

Where each dollar of operating cash went, fiscal 2022

  • Capital spending10¢$8.6M
  • Kept or used elsewhere90¢$73.7M

Out of $82.4M of cash from operations.4

Financial statements

Revenue56784$333.0M in 2022+70% since 2016
0$100.0M$200.0M$300.0M$400.0M2016: $196.1M$196.1M20162017: $200.8M$200.8M2017+2%2018: $213.6M$213.6M2018+6%2019: $201.0M$201.0M2019−6%2020: $253.7M$253.7M2020+26%2021: $317.9M$317.9M2021+25%2022: $333.0M$333.0M2022+5%
Gross profit56784$188.4M in 2022+48% since 2016
0$100.0M$200.0M$300.0M2016: $127.2M$127.2M20162017: $124.3M$124.3M2017−2%2018: $131.0M$131.0M2018+5%2019: $118.7M$118.7M2019−9%2020: $156.2M$156.2M2020+32%2021: $201.1M$201.1M2021+29%2022: $188.4M$188.4M2022−6%
Operating income56784$54.4M in 2022+6% since 2016
0$25.0M$50.0M$75.0M$100.0M2016: $51.4M$51.4M20162017: $37.4M$37.4M2017−27%2018: $31.6M$31.6M2018−16%2019: $32.7M$32.7M2019+4%2020: $61.3M$61.3M2020+88%2021: $93.0M$93.0M2021+52%2022: $54.4M$54.4M2022−42%
Net income56784$42.5M in 2022+32% since 2016
0$20.0M$40.0M$60.0M$80.0M2016: $32.2M$32.2M20162017: $21.6M$21.6M2017−33%2018: $23.8M$23.8M2018+11%2019: $24.4M$24.4M2019+2%2020: $46.2M$46.2M2020+89%2021: $71.4M$71.4M2021+55%2022: $42.5M$42.5M2022−41%
Fiscal year2016201720182019202020212022
Revenue$196.1M5$200.8M6$213.6M7$201.0M8$253.7M4$317.9M4$333.0M4
Cost of revenue$68.9M5$76.5M6$82.5M7$82.3M8$97.4M4$116.7M4$144.7M4
Gross profit$127.2M5$124.3M6$131.0M7$118.7M8$156.2M4$201.1M4$188.4M4
Research and development$14.2M5$16.0M6$16.6M7$17.8M8$23.7M4$23.9M4$24.3M4
Operating expenses$134.0M4
Operating income$51.4M5$37.4M6$31.6M7$32.7M8$61.3M4$93.0M4$54.4M4
Interest$897.0K5$1.6M6$1.5M7$1.9M8$2.6M4$1.9M4$1.2M4
Income before tax$54.3M4
Income tax$18.4M5$14.9M6$6.5M7$7.2M8$13.1M4$19.0M4$11.9M4
Net income$32.2M5$21.6M6$23.8M7$24.4M8$46.2M4$71.4M4$42.5M4
Earnings per share$0.775$0.516$0.567$0.578$1.084$1.654$0.974
Earnings per share (diluted)$0.765$0.516$0.567$0.578$1.074$1.624$0.964
Shares (weighted, basic)43.6M shares4
Shares (weighted, diluted)44.4M shares4

Compare Meridian Bioscience with another company

Corporate structure

Meridian Bioscience sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Meridian Bioscience

  • VANGUARD GROUP INC Filed SC 13G/A on Meridian Bioscience, latest Feb 9, 2023 (2 filings since Feb 10, 2022)
  • Magnetar Financial LLC Filed SC 13D/A on Meridian Bioscience, latest Feb 3, 2023 (5 filings since Sep 19, 2022)
  • ROYCE & ASSOCIATES LP Filed SC 13G/A on Meridian Bioscience, latest Jan 31, 2023 (2 filings since Jan 21, 2022)
  • BlackRock Filed SC 13G/A on Meridian Bioscience, latest Jan 26, 2023 (4 filings since Jan 25, 2022)
  • Impactive Capital LP Filed SC 13D/A on Meridian Bioscience, latest Oct 28, 2022 (5 filings since Feb 4, 2022)
  • EARNEST PARTNERS LLC Filed SC 13G/A on Meridian Bioscience, latest Aug 10, 2022 (2 filings since Feb 10, 2022)
  • James E. Flynn Filed SC 13G/A on Meridian Bioscience, latest Feb 11, 2022
  • RENAISSANCE TECHNOLOGIES LLC Filed SC 13G/A on Meridian Bioscience, latest Feb 11, 2022
  • Meridian Bioscience Cincinnati, Ohio, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Meridian Bioscience reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$968.0K4 Sep 30, 2022$989.0K4 Sep 30, 2021−2.1%
Buildings and improvements$33.0M4 Sep 30, 2022$32.8M4 Sep 30, 2021+0.7%
Property and equipment, before depreciation$124.1M4 Sep 30, 2022$122.2M4 Sep 30, 2021+1.6%
Accumulated depreciation$79.2M4 Sep 30, 2022$78.9M4 Sep 30, 2021+0.3%
Property and equipment, net$44.9M4 Sep 30, 2022$43.2M4 Sep 30, 2021+3.8%
Operating-lease assets (leased space)$5.8M4 Sep 30, 2022$5.8M4 Sep 30, 2021+1.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$81.5M4 Sep 30, 2022$49.8M4 Sep 30, 2021+63.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$116.3M4 Sep 30, 2022$114.7M4 Sep 30, 2021+1.4%
Intangible assets, net (excluding goodwill)$74.1M4 Sep 30, 2022$84.2M4 Sep 30, 2021−11.9%
Indefinite-lived intangibles (excluding goodwill)$04 Sep 30, 2022$04 Sep 30, 2021
Finite-lived intangibles, gross$127.4M4 Sep 30, 2022$136.0M8 Oct 31, 2021−6.3%
Accumulated amortization$53.2M4 Sep 30, 2022$51.8M8 Oct 31, 2021+2.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$67.8M4 Sep 30, 2022$76.8M4 Sep 30, 2021−11.7%
Raw materials$15.7M4 Sep 30, 2022$14.8M4 Sep 30, 2021+5.9%
Work in process$21.6M4 Sep 30, 2022$25.1M4 Sep 30, 2021−14.0%

Leadership

Who has led Meridian Bioscience, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William J. Motto2006–2008
  2. John A. Kraeutler2008–2017
  3. Amy Winslow2016–2017
  4. John P. Kenny2017–2023

Chair

  1. William J. Motto2006–2014
  2. John A. Kraeutler2014–2017

President

  1. Antonio Interno2006
  2. John A. Kraeutler2006–2007

Chief financial officer

  1. Melissa Lueke2006–2019
  2. Bryan T. Baldasare2019–2021
  3. Andrew S. Kitzmiller2022–2023

Chief operating officer

  1. John A. Kraeutler2006–2007
19801990200020102020
Board members and other officers (24)

Timeline

  1. Feb 1, 20238-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale46
  2. Dec 12, 20228-K Entered a material agreement; Other events47
  3. Nov 22, 20228-K Results of operations; Regulation FD disclosure48
  4. Oct 11, 20228-K Shareholder vote; Other events49
  5. Sep 30, 20228-K Other events50
  6. Aug 5, 20228-K Results of operations; Regulation FD disclosure51
  7. Jul 29, 20228-K Other events52
  8. Jul 7, 20228-K Results of operations53
  9. Jul 7, 20228-K Entered a material agreement; Completed an acquisition or sale; Executive or director change54
  10. May 6, 20228-K Results of operations; Regulation FD disclosure55
  11. May 2, 20228-K Other events56
  12. Apr 7, 20228-K Results of operations57
  13. Oct 11, 2017New chief executive John P. Kenny becomes CEO14
  14. Mar 28, 2016New chief executive Amy Winslow becomes CEO15
  15. Feb 1, 2008New chief executive John A. Kraeutler becomes CEO16
  16. Jan 26, 2006New chief executive William J. Motto becomes CEO17
  17. Feb 26, 1992Went public Listed on NASDAQ1
  18. 1977Founded Founded1

Calendar

When it reported results

  1. Nov 22, 2022Reported quarterly or annual results48
  2. Aug 5, 2022Reported quarterly or annual results51
  3. Jul 7, 2022Reported quarterly or annual results53
  4. May 6, 2022Reported quarterly or annual results55
  5. Apr 7, 2022Reported quarterly or annual results57
  6. Feb 4, 2022Reported quarterly or annual results58
  7. Nov 12, 2021Reported quarterly or annual results59

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

135 filings to the SEC since October 2021: 3 annual reports, 4 quarterly reports, 19 major events, 52 insider forms, 22 large holders, 35 other. The latest 20:

  1. Feb 13, 202315-12G EDGAR
  2. Feb 9, 202310-Q EDGAR
  3. Feb 9, 2023SC 13G/A SCHEDULE 13G/A EDGAR
  4. Feb 3, 2023EFFECT EDGAR
  5. Feb 3, 2023EFFECT EDGAR
  6. Feb 3, 2023EFFECT EDGAR
  7. Feb 3, 2023EFFECT EDGAR
  8. Feb 3, 2023EFFECT EDGAR
  9. Feb 3, 2023SC 13D/A EDGAR
  10. Feb 2, 2023S-8 POS EDGAR
  11. Feb 2, 2023S-8 POS EDGAR
  12. Feb 2, 2023S-8 POS EDGAR
  13. Feb 2, 2023S-8 POS EDGAR
  14. Feb 2, 2023S-8 POS EDGAR
  15. Feb 2, 2023S-8 POS EDGAR
  16. Feb 2, 2023S-8 POS EDGAR
  17. Feb 2, 2023S-8 POS EDGAR
  18. Feb 2, 2023S-8 POS EDGAR
  19. Feb 2, 2023S-8 POS EDGAR
  20. Feb 2, 2023S-8 POS EDGAR

The 135 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 1 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 27, 2022Kenny John P.Chief Executive OfficerSale61,437$30.39$1.9MForm 4
Jun 24, 2022Kenny John P.Chief Executive OfficerSale13,559$30.00$406.8KForm 4
Jun 23, 2022Kenny John P.Chief Executive OfficerSale19,956$29.98$598.3KForm 4
Jun 22, 2022Kenny John P.Chief Executive OfficerSale44,651$29.72$1.3MForm 4
Feb 25, 2022Kitzmiller Andrew S.Executive Vice President & CFOBuy4,028$24.87$100.2KForm 4
Feb 15, 2022WELTZIEN LOURDESExecutive VP, Life ScienceSale20,000$25.60$512.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Members of Congress who traded it

5 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Feb 23, 2021Tom MalinowskiDemocratic, HouseSale$1,001 - $15,000+196.7%Report
Nov 13, 2020Tom MalinowskiDemocratic, HouseSale$1,001 - $15,000+212.0%Report
Sep 16, 2020Tom MalinowskiDemocratic, HousePartial sale$1,001 - $15,000+224.3%Report
Sep 15, 2020Tom MalinowskiDemocratic, HouseSale$1,001 - $15,000+223.3%Report
Aug 31, 2020Tom MalinowskiDemocratic, HouseSale$1,001 - $15,000+218.3%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Meridian Bioscience is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMERIDIAN BIOSCIENCE INC2
  • CIK0000794172
  • Employer ID (EIN)31-08881972
  • Filer statusLarge accelerated filer2
  • Incorporated inOhio2
  • Fiscal year endsSeptember 302
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances2
  • Business address3471 River Hills Dr, Cincinnati, OH 452442
  • Mailing address3471 River Hills Drive, Cincinnati, OH 452442
  • Phone51327137002
  • Shares outstanding44,041,635 as of Jan 30, 202311
  • Public float$1.1B as of Mar 31, 202268
  • On EDGAR sinceAug 2, 19952
  • Filings1,370 in all: 4 (721), 8-K (166), SC 13G/A (86), 10-Q (83), 4/A (34), DEF 14A (27), 10-K (26), SC 13G (25)2
    All 45 form types

    3 (24), UPLOAD (19), CORRESP (15), S-8 POS (13), 11-K (12), SC 13D/A (11), 8-K/A (9), DEFA14A (9), S-8 (9), SD (9), ARS (7), EFFECT (7), 5 (6), 10-Q/A (5), POS AM (5), S-3 (5), SC TO-I/A (4), PRE 14A (3), S-3ASR (3), SC 13D (3), 10-K/A (2), 10-K405 (2), 424B1 (2), 424B3 (2), S-3/A (2), SEC STAFF LETTER (2), T-3/A (2), 10-K405/A (1), 15-12G (1), 25-NSE (1), 424B5 (1), 5/A (1), DEFM14A (1), PREM14A (1), S-3MEF (1), SC TO-I (1), T-3 (1)

  • Latest filingsAnnual report (10-K) Nov 22, 2022
    Quarterly report (10-Q) Feb 9, 2023
    Proxy statement (DEF 14A) Dec 15, 2021
    Latest 8-K (8-K) Feb 1, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
  56. 56
    SEC EDGAROther events
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68